Article information
Full text is only aviable in PDF
References
[1.]
D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, et al.
Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis.
N Engl J Med, 356 (2007), pp. 1809-1822
[2.]
S.R. Cummings, D.M. Black, D.E. Thompson, W.B. Applegate, E. Barret-Connor, T.A. Musliner, et al.
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
JAMA, 280 (1998), pp. 2077-2082
[3.]
I.R. Reid, P. Miller, K. Lyles, W.D. Fraser, J.P. Brown, Y. Saidi, et al.
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
N Engl J Med, 353 (2005), pp. 898-908
[4.]
D. Hosking, K. Lyles, J.P. Brown, W.D. Fraser, P. Miller, M.D. Curiel, et al.
Longterm control of bone turnover in Paget's disease with zoledronic acid and risedronate.
J Bone Miner Res, 22 (2007), pp. 142-148
[5.]
K. Lyles, C. Colon-Emeric, J. Magaziner, J. Adachi, C. Pieper, C. Mautalen, et al.
Zoledronic acid clinical fractures mortality after hip fracture.
N Engl J Med, 357 (2007), pp. 1799-1809
Copyright © 2008. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
